Year archive

Genmab — 2026 filings

All 64 regulatory filings released by Genmab (GMAB) in 2026, sourced directly from the official regulator.

64 Filings

2026 Period

2026 filings (64)

Filing	Released	Lang
Major Shareholder Announcement Regulatory Filings	2026-05-08	Danish
Major Shareholder Announcement Regulatory Filings	2026-05-08	Danish
Major Shareholder Announcement Regulatory Filings	2026-05-08	Danish
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-05-07	English
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-04-17	English
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-04-17	English
Genmab A/S Share Capital Reduction Share Issue/Capital Change	2026-04-17	English
Genmab A/S Share Capital Reduction Share Issue/Capital Change	2026-04-17	English
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-04-14	English
Major Shareholder Announcement Major Shareholding Notification	2026-04-14	English
Major Shareholder Announcement Major Shareholding Notification	2026-04-14	English
Major Shareholder Announcement Major Shareholding Notification	2026-04-14	English
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-04-14	English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 Earnings Release Q1 2026	2026-04-14	English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 Earnings Release Q1 2026	2026-04-14	English
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-04-01	English
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Director's Dealing	2026-04-01	English
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Director's Dealing	2026-04-01	English
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-04-01	English
Major Shareholder Announcement Major Shareholding Notification	2026-04-01	English
Major Shareholder Announcement Major Shareholding Notification	2026-04-01	English
Major Shareholder Announcement Major Shareholding Notification	2026-04-01	English
Major Shareholder Announcement Major Shareholding Notification	2026-03-30	English
Major Shareholder Announcement Major Shareholding Notification	2026-03-30	English
Major Shareholder Announcement Major Shareholding Notification	2026-03-30	English
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-03-23	English
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-03-19	English
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-03-19	English
Completion of Share Buy-back Program Transaction in Own Shares	2026-03-16	English
Completion of Share Buy-back Program Transaction in Own Shares	2026-03-16	English
Transactions in Connection with Share Buy-back Program Transaction in Own Shares	2026-03-09	English
Transactions in Connection with Share Buy-back Program Transaction in Own Shares	2026-03-09	English
Correction to Company Announcement No. 13 of March 2, 2026 Director's Dealing	2026-03-02	English
Correction to Company Announcement No. 13 of March 2, 2026 Director's Dealing	2026-03-02	English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Director's Dealing	2026-03-02	English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Director's Dealing	2026-03-02	English
Transactions in Connection with Share Buy-back Program Transaction in Own Shares	2026-03-02	English
Transactions in Connection with Share Buy-back Program Transaction in Own Shares	2026-03-02	English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Director's Dealing	2026-02-27	English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Director's Dealing	2026-02-27	English
Capital Increase in Genmab as a Result of Employee Warrant Exercise Share Issue/Capital Change	2026-02-24	English
Capital Increase in Genmab as a Result of Employee Warrant Exercise Share Issue/Capital Change	2026-02-24	English
6-K - GENMAB A/S (0001434265) (Filer) Foreign Filer Report	2026-02-23	English
Transactions in Connection with Share Buy-back Program Transaction in Own Shares	2026-02-23	English
Transactions in Connection with Share Buy-back Program Transaction in Own Shares	2026-02-23	English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Director's Dealing	2026-02-20	English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Director's Dealing	2026-02-20	English
Genmab Announces Initiation of Share Buy-Back Program Transaction in Own Shares	2026-02-17	English
Genmab Announces Initiation of Share Buy-Back Program Transaction in Own Shares	2026-02-17	English
Genmab Publishes 2025 Annual Report Annual Report (ESEF) FY 2025	2026-02-17	English
Genmab Publishes 2025 Annual Report Annual Report FY 2025	2026-02-17	English
Genmab Publishes 2025 Annual Report Report Publication Announcement	2026-02-17	English
20-F Filing Annual Report FY 2025	2026-02-17	English
6-K Filing Foreign Filer Report	2026-02-17	English
S-8 Filing Registration Form	2026-02-17	English
SCHEDULE 13G/A Filing Major Shareholding Notification	2026-02-17	English
6-K Filing Foreign Filer Report	2026-02-03	English
6-K Filing Foreign Filer Report	2026-01-29	English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 Earnings Release FY 2025	2026-01-21	English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 Report Publication Announcement	2026-01-21	English
6-K Filing Foreign Filer Report	2026-01-21	English
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Earnings Release Q1 2026	2026-01-16	English
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Regulatory Filings	2026-01-16	English
6-K Filing Foreign Filer Report	2026-01-16	English

Filings by year

2026 64 filings
2025 190 filings
2024 204 filings
2023 149 filings
2022 190 filings
2021 226 filings
2020 167 filings
2019 213 filings
2018 68 filings
2017 124 filings
2016 229 filings
2015 128 filings
2014 107 filings
2013 132 filings
2012 98 filings
2011 97 filings
2010 133 filings
2009 121 filings
2008 109 filings
2007 70 filings